Project Search Results

Select

Research Categorization

Operator
Operator

Project Details

Operator
Operator

Contact Researcher and Awardee Organization

Operator
Operator

Funding Organization

Operator
Operator
Operator
Operator
ListGraphMap
Displaying 1 - 10 of 62 Projects
Project # Contact PI Funding Organization Fiscal Year
Noninvasive stimulation of the brain dopamine system: A study combining neuromodulation to multimodal neuroimaging
EUJPND-AcadFinland-Juho-591 Juho, Joutsa Academy of Finland 2016
Singing and Playing in the Recovering and Degenerating Brain: Efficacy and Neural Mechanisms of Music in Stroke, Brain Injury, and Alzheimer’s Disease
EUJPND-AcadFinland-Teppo-605 Teppo, Särkämö Academy of Finland 2016
Singing and Playing in the Recovering and Degenerating Brain: Efficacy and Neural Mechanisms of Music in Stroke, Brain Injury, and Alzheimer’s Disease
EUJPND-AcadFinland-Teppo-606 Teppo, Särkämö Academy of Finland 2016
The role of Prolyl oligopeptidase (POP) and its inhibition on ?-synuclein aggregation and Parkinson’s disease models
EUJPND-AcadFinland-Timo-609 Timo, Myöhänen Academy of Finland 2016
Control theory for neural synchrony: modeling based on optogenetics data, anda closed-loop alteration of pathological brain oscillations
EUJPND-FranceANR-CHAILLET-629 CHAILLET, Antoine Agence Nationale de la Recherche (ANR) 2016
Dopamine Gene therapy for the treatment of Motor and Non-motor symptoms of Parkinson disease. A translational program from Non-Human primate models to patients
EUJPND-FranceANR-PALFI-651 PALFI, Stéphane Agence Nationale de la Recherche (ANR) 2016
3D in-line blood brain barrier pharmacology testing platform
EUJPND-FranceANR-Roisin-656 Roisin, OWENS Agence Nationale de la Recherche (ANR) 2016
Symptomatic Treatment of Vascular Cognitive Impairment
EUJPND-AlzNederland-Prins-1627 Prins, N.P. Alzheimer Nederland 2016
Small molecule induced regeneration for Parkinson’s disease treatment
ARUK-DC2016-1 Jens Christian Schwamborn Alzheimer's Research UK 2016
Fractalkine agonists to treat neurodegenerative disease
ARUK-DC2016-2 David Morgan Alzheimer's Research UK 2016